Emergent BioSolutions (EBS) EBIAT (2016 - 2025)
Historic EBIAT for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $51.2 million.
- Emergent BioSolutions' EBIAT fell 5540.07% to $51.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $75.9 million, marking a year-over-year increase of 13635.06%. This contributed to the annual value of -$190.6 million for FY2024, which is 7493.75% up from last year.
- Latest data reveals that Emergent BioSolutions reported EBIAT of $51.2 million as of Q3 2025, which was down 5540.07% from -$12.0 million recorded in Q2 2025.
- Over the past 5 years, Emergent BioSolutions' EBIAT peaked at $193.1 million during Q4 2021, and registered a low of -$283.1 million during Q2 2024.
- Moreover, its 5-year median value for EBIAT was -$31.3 million (2024), whereas its average is -$44.0 million.
- As far as peak fluctuations go, Emergent BioSolutions' EBIAT plummeted by 1048000.0% in 2022, and later surged by 65555.56% in 2025.
- Quarter analysis of 5 years shows Emergent BioSolutions' EBIAT stood at $193.1 million in 2021, then tumbled by 134.7% to -$67.0 million in 2022, then rose by 26.12% to -$49.5 million in 2023, then soared by 36.77% to -$31.3 million in 2024, then skyrocketed by 263.58% to $51.2 million in 2025.
- Its EBIAT was $51.2 million in Q3 2025, compared to -$12.0 million in Q2 2025 and $68.0 million in Q1 2025.